(News Bulletin 247) – AstraZeneca announced on Thursday that one of its star immunotherapies, Imfinzi, had succeeded in improving the survival of patients suffering from a form of lung cancer whose tumor is operable.
This phase III trial established that treatment with Imfinzi, before and after surgery, ‘significantly’ increased event-free survival (i.e. without recurrence or progression of the disease) in patients with non-small cell cancer.
‘Patients with non-small cell cancer face unacceptably high rates of disease recurrence, despite chemotherapy treatment and surgery,’ says branch head Susan Galbraith. oncology from AstraZeneca.
“We have demonstrated that the addition of Imfinzi, both before and after surgery, significantly improves patient survival without disease recurrence or progression,” she added.
Listed on the London Stock Exchange, AstraZeneca shares were up 0.4% on Thursday mid-morning following this announcement.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
